» Articles » PMID: 37093467

Cloning and Recombinant Protein Expression in Lactococcus Lactis

Overview
Specialty Molecular Biology
Date 2023 Apr 24
PMID 37093467
Authors
Affiliations
Soon will be listed here.
Abstract

The Lactococcus lactis, a Gram-positive bacteria, is an ideal expression host for the overproduction of heterologous proteins in a properly folded and functional form. L. lactis has been identified as an efficient cell factory, generally recognized as safe (GRAS), has a long history of safe use in food production, and is known to have probiotic properties. Key desirable features of L. lactis include the following: (1) rapid growth to high cell densities, not requiring aeration which facilitates large-scale fermentation; (2) its Gram-positive nature precludes the presence of contaminating endotoxins; (3) the capacity to secrete stable recombinant protein into the growth medium with few proteases resulting in a properly folded, full-length protein; and (4) the availability of diverse expression vectors facilitating various cloning options. We have previously described production of several recombinant proteins with varying degrees of predicted structural complexities using the L. lactis pH-dependent P170 promoter. The purpose of this chapter is to provide a detailed protocol for facilitating wider application of L. lactis as a reliable platform for expression of heterologous recombinant proteins in soluble form. Here, we present details of the various steps involved such as cloning of the target gene in appropriate expression plasmid vector, determination of the expression levels of the heterologous protein, and initial purification of the expressed soluble recombinant protein of interest.

References
1.
Jorgensen C, Vrang A, Madsen S . Recombinant protein expression in Lactococcus lactis using the P170 expression system. FEMS Microbiol Lett. 2013; 351(2):170-8. DOI: 10.1111/1574-6968.12351. View

2.
Acquah F, Obboh E, Asare K, Boampong J, Nuvor S, Singh S . Antibody responses to two new Lactococcus lactis-produced recombinant Pfs48/45 and Pfs230 proteins increase with age in malaria patients living in the Central Region of Ghana. Malar J. 2017; 16(1):306. PMC: 5540549. DOI: 10.1186/s12936-017-1955-0. View

3.
Baldwin S, Roeffen W, Singh S, Tiendrebeogo R, Christiansen M, Beebe E . Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen. Vaccine. 2016; 34(19):2207-15. DOI: 10.1016/j.vaccine.2016.03.016. View

4.
Mistarz U, Singh S, Nguyen T, Roeffen W, Yang F, Lissau C . Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite. Pharm Res. 2017; 34(9):1970-1983. DOI: 10.1007/s11095-017-2208-1. View

5.
Roeffen W, Theisen M, van de Vegte-Bolmer M, van Gemert G, Arens T, Andersen G . Transmission-blocking activity of antibodies to Plasmodium falciparum GLURP.10C chimeric protein formulated in different adjuvants. Malar J. 2015; 14:443. PMC: 4640242. DOI: 10.1186/s12936-015-0972-0. View